Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

Global FFR as Prognosis in CAD Patients without Ischemia

Global fractional flow reserve (FFR) results from adding up FFR values of the three major coronary arteries. This figure represents the physiological atherosclerosis burden and can predict events at long term in patients without stenosis leading to ischemia. This recent study published in JAHA looked at major cardiovascular events (death, infarction and revascularization) at 5<a href="https://solaci.org/en/2020/12/16/global-ffr-as-prognosis-in-cad-patients-without-ischemia/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

In-Stent Restenosis Treatment: Meta-Analysis of 10 Randomized Studies

The best strategy to treat in stent restenosis continues to be a dilemma. A new drug eluting stent (DES) seems to be the simplest treatment, even though it adds metal layers that will make it harder and harder to retreat. Drug coated balloons might be a viable alternative seeing as it seems to enable retreatment,<a href="https://solaci.org/en/2020/11/18/in-stent-restenosis-treatment-meta-analysis-of-10-randomized-studies/" title="Read more" >...</a>

Drug-Coated Balloons in Critical Ischemia: The Paradigm of Randomized Evidence vs. Logbooks

This research, which included thousands of patients treated for chronic inferior limb ischemia with drug-coated balloons, did not show an association between said devices and the increased mortality observed in some randomized trials.  The long-term evidence from plenty of real-world patients contradicts what has been shown in randomized trials, leaving an information gap. Endovascular revascularization<a href="https://solaci.org/en/2020/10/13/drug-coated-balloons-in-critical-ischemia-the-paradigm-of-randomized-evidence-vs-logbooks/" title="Read more" >...</a>

IN.PACT AV ACCESS | Drug-Coated Balloons for Dialysis Fistulas

The IN.PACT AV Access study, recently published in the New England Journal of Medicine (NEJM), showed that drug-coated balloons are superior for the treatment of stenotic lesions in arteriovenous fistulas for dialysis compared with conventional balloons. Dialysis fistulas are an unknown territory for paclitaxel-eluting balloons, since the formal recommendation in the guidelines is conventional angioplasty<a href="https://solaci.org/en/2020/09/30/in-pact-av-access-drug-coated-balloons-for-dialysis-fistulas/" title="Read more" >...</a>

SOLACI PERIPHERAL | 3rd Clinical Case: Femoral PCI

In keeping with its Clinical Case Discussion Program, SOLACI’s peripheral interventions department, SOLACI Peripheral, presents the third clinical case, to promote knowledge exchange across the entire Latin American hemodynamics community.  Share your thoughts on case and resolution in the comments and answer the questions at the end of the article. Femoral PCI Authors: MD Mauricio Cavalieri<a href="https://solaci.org/en/2020/08/24/solaci-peripheral-3rd-clinical-case-femoral-pci/" title="Read more" >...</a>

Seguridad de los balones con paclitaxel en enfermedad vascular periférica

Peripheral Artery Disease: Underestimated and Undertreated

Compared against coronary artery disease (CAD) or cerebrovascular disease patients, peripheral artery disease (PAD) patients have lower chances of receiving medication proved to be clinically effective such as statins (despite running the same risk, perhaps even higher risk).  The message is we should be more active both in finding risk factors in PAD patients, and<a href="https://solaci.org/en/2020/08/03/peripheral-artery-disease-underestimated-and-undertreated/" title="Read more" >...</a>

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Coated Balloons in Infrapopliteal Disease: Much Ado About Nothing

The revascularization of tibial arteries in patients with critical lower limb ischemia using drug-coated balloons vs. conventional angioplasty resulted in comparable long-term outcomes in terms of both safety and efficacy. Paclitaxel exposure was not related to a higher risk of amputation or all-cause mortality at 5 years (which is the good news for much questioned drug-coated<a href="https://solaci.org/en/2020/03/16/drug-coated-balloons-in-infrapopliteal-disease-much-ado-about-nothing/" title="Read more" >...</a>

mas-leido-febrero-eng-420x283-compressor

The Most Read Scientific Articles of February

01- Alternatives for Patients Allergic to Aspirin The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a recommendation to use monotherapy with the most potent antiaggregant we<a href="https://solaci.org/en/2020/03/11/the-most-read-scientific-articles-of-february/" title="Read more" >...</a>

Consensus on How to Conduct Follow-Up in Peripheral Vascular Disease

Peripheral vascular disease involves multiple areas and, therefore, can have very different presentations (from complete lack of symptoms to disabling symptoms). Depending on clinical presentation, general condition, anatomical localization, and lesion extension, revascularization can be indicated alongside optimal medical treatment. In 2017, guidelines with indications for revascularization were published; however, maintaining long-term patency can be<a href="https://solaci.org/en/2019/12/27/consensus-on-how-to-conduct-follow-up-in-peripheral-vascular-disease/" title="Read more" >...</a>

Drug Coated Balloons vs. Drug Eluting Stents in Primary PCI

There might come the time when we are finally able to leave nothing behind, at least in the context of primary PCI. The REVELATION study, soon to be published in J Am Coll Cardiol Intv, has shown that paclitaxel coated balloons resulted non inferior to drug eluting stents (DES) in terms of FFR (fractional flow<a href="https://solaci.org/en/2019/09/19/drug-coated-balloons-vs-drug-eluting-stents-in-primary-pci/" title="Read more" >...</a>